Rafael Holdings (Rafael Holdings) Cash, Cash Equivalents, Marketable Securities : $71.72 Mil (As of Jan. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Rafael Holdings Cash, Cash Equivalents, Marketable Securities?

Rafael Holdings's quarterly cash, cash equivalents, marketable securities declined from Jul. 2023 ($79.51 Mil) to Oct. 2023 ($72.09 Mil) but then stayed the same from Oct. 2023 ($72.09 Mil) to Jan. 2024 ($71.72 Mil).

Rafael Holdings's annual cash, cash equivalents, marketable securities increased from Jul. 2021 ($7.85 Mil) to Jul. 2022 ($63.24 Mil) and increased from Jul. 2022 ($63.24 Mil) to Jul. 2023 ($79.51 Mil).

Rafael Holdings Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Rafael Holdings's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rafael Holdings Cash, Cash Equivalents, Marketable Securities Chart

Rafael Holdings Annual Data

Trend

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

12.02

6.21

7.85

63.24

79.51

Rafael Holdings Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															88.87	82.40	79.51	72.09	71.72

Rafael Holdings Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Rafael Holdings (NYSE:RFL) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Rafael Holdings Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Rafael Holdings's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Rafael Holdings (Rafael Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Rafael Holdings Inc (NYSE:RFL) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

520 Broad Street, Newark, NJ, USA, 07102

Website

https://www.rafaelholdings.com

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.

Executives

I9 Plus, Llc	10 percent owner	153 BOOTH AVE, ENGLEWOOD NJ 07631
Howard S Jonas	director
Mary Margaret Huizinga	officer: Chief Devel. & Medical Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Ashok D Marin	officer: Chief Legal Officer	C/O LIPOSCIENCE, INC., 2500 SUMNER BOULEVARD, RALEIGH NC 27616
Patrick Fabbio	officer: Chief Financial Officer	2 PITNEY COURT, BASKING RIDGE NJ 07920
Mark Anthony Mccamish	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Shannon Thyme Klinger	director	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Ameet Mallik	officer: CHIEF EXECUTIVE OFFICER	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
William Conkling	officer: Chief Commercial Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Rachel Jonas	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Boris C Pasche	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Michael J Weiss	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
Stephen M Greenberg	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
David Polinsky	officer: Chief Financial Officer	90 BOOTH AVENUE, ENGLEWOOD NJ 07631
Menachem Ash	director, officer: President	C/O IDT CORPORATION, 520 BROAD STREET, NEWARK NJ 07102